Combining RNAi-based functional genomic screens with automated high-content image analysis of cells could become a new way for drug companies to identify novel targets, according to a recent study.

Earlier this month, researchers led by Marino Zerial, a director at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, and their collaborators published a paper in Nature using this approach to study the role of human kinases in endocytosis [Nature, Vol. 436, 7 July 2005, p. 78-86].

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.